ArticleJournal of oncology navigation & survivorship2024
Mixed Methods Evaluation of Gaps and Barriers in Delivery of Precision Oncology in Advanced Lung Cancer.
Article in Journal of oncology navigation & survivorship, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Lung cancer is the leading cause of cancer mortality and has well described disparities in outcomes. Significant survival gains in non-small cell lung cancer (NSCLC) have been achieved due to precision oncology, however, shortfalls in its delivery will further exacerbate disparities. Patient navigation is an approach to address cancer care disparities. We sought to characterize the barriers and facilitators to precision oncology through a mixed methods approach. Methods: We performed a cross-sectional study of patient navigators, pathologists, and clinicians in North Carolina (NC). We conducted surveys and interviews to assess barriers and facilitators to effective delivery of precision medicine for patients with advanced NSCLC, including next generation sequencing (NGS) and use of targeted therapies and immunotherapy. We recruited both community-based and academic cancer providers across the state. Results: Fifty-six participants completed the survey, with representation from both community and academic sites, and five completed interviews. Clinicians reported gaps in delivery of precision medicine as well as knowledge gaps, feeling "not at all" or "a little bit" knowledgeable about NGS (19%), liquid biopsy (32%) and targeted therapies (19%). Navigators endorsed common conversations about precision medicine but felt "somewhat" or "very" uncomfortable discussing NGS (38%), targeted therapies (31%), and limited confidence in resolving barriers. Qualitative interviews highlighted potential solutions including financial aid, dedicated pathology support, use of liquid biopsy, and partnership with social work. Conclusion: Academic and community-based clinicians in N.C. reported gaps in delivery of precision oncology in advanced NSCLC. Navigators reported a significant role in precision oncology education and delivery but limited confidence in doing so. Qualitative data highlight potential strategies for improving access. These findings suggest a need for further interventions and education to support clinicians and navigators disseminating precision oncology.
Identifiers
42459601PMC13372248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.